- Home
- AYTU vs EDSA Comparison
AYTU vs EDSA Comparison
Compare AYTU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- EDSA
- Stock Information
- Founded
- AYTU N/A
- EDSA 2015
- Country
- AYTU United States
- EDSA Canada
- Employees
- AYTU N/A
- EDSA N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- EDSA Health Care
- Exchange
- AYTU Nasdaq
- EDSA Nasdaq
- Market Cap
- AYTU 9.8M
- EDSA 6.1M
- IPO Year
- AYTU N/A
- EDSA N/A
- Fundamental
- Price
- AYTU $1.38
- EDSA $1.73
- Analyst Decision
- AYTU
- EDSA Strong Buy
- Analyst Count
- AYTU 0
- EDSA 1
- Target Price
- AYTU N/A
- EDSA $21.00
- AVG Volume (30 Days)
- AYTU 37.2K
- EDSA 30.8K
- Earning Date
- AYTU 02-12-2025
- EDSA 02-07-2025
- Dividend Yield
- AYTU N/A
- EDSA N/A
- EPS Growth
- AYTU N/A
- EDSA N/A
- EPS
- AYTU N/A
- EDSA N/A
- Revenue
- AYTU $79,759,000.00
- EDSA N/A
- Revenue This Year
- AYTU N/A
- EDSA N/A
- Revenue Next Year
- AYTU N/A
- EDSA N/A
- P/E Ratio
- AYTU N/A
- EDSA N/A
- Revenue Growth
- AYTU N/A
- EDSA N/A
- 52 Week Low
- AYTU $1.30
- EDSA $1.55
- 52 Week High
- AYTU $3.45
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- AYTU 33.90
- EDSA 31.51
- Support Level
- AYTU $1.30
- EDSA $1.73
- Resistance Level
- AYTU $1.47
- EDSA $1.99
- Average True Range (ATR)
- AYTU 0.12
- EDSA 0.19
- MACD
- AYTU -0.01
- EDSA 0.02
- Stochastic Oscillator
- AYTU 17.78
- EDSA 18.00
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.